Clinical trial · Observational
Development and Validation of a Tumour Oxygenation Monitoring Probe
NCT03982355CI-TRIAL-00080866completedResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Laboratory based study in which novel tissue oxygenation probe with the potential provide novel means for assessing response to cancer treatment will be developed and validated.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DRS probe | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Breast Cancer
- description
- Anonymised MRI scans (pre-therapy) of locally advanced breast cancer sufferers.
- interventionNames
- Device: DRS probe
- label
- Rectal Cancer
- description
- Anonymised MRI scans (pre-therapy) of locally advanced rectal cancer sufferers.
- interventionNames
- Device: DRS probe
Primary outcomes (1)
- measure
- Count of MRIs Successfully Modelled for Oxygen Correlation
- timeFrame
- MRIs were 3D modelled - single time point at time of MRI
- description
- Number of MRIs 3D modelled for oxygenation sensor development Note: this outcome measure was orginally expressed as "Oxygenation Correlation" though this was modeled and therefore we have expressed it as above
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * MRIs from Breast or Rectal Cancer patients (10 of each) * Locally advanced Cancers (Stage 2 or 3) * Patients who went on to receive neoadjuvant chemoradiotherapy. * Anonymised scans Exclusion Criteria: * MRIs from patients under the age of 18, or older than 99 years old will be excluded. * MRIs from patients who did not receive neoadjuvant therapy for cancer will be excluded.
References
Publications (0)
Data not yet available
No reference posted for this study.